New clinical data suggest that Johnson & Johnson’s pharmaceutical arm confirms that the COVID-19 vaccine candidate was able to stimulate an immune response that lasted slightly longer than two months, or 71 days, below 805 study participants.
Announced via a Press release and published in The New England Journal of Medicine, the company said its vaccine, called Ad26.COV2.S, elicits an immune response against COVID-19 antibodies after a single dose.
Other approved PVizer and Moderna COVID-19 vaccines require two vaccinations within a few weeks of each other. Receiving only one shot will result in less immunity.
WHAT EXPERTS SS ABOUT EFFORT OF THE INTING
CDC OFFICERS ENSURE SAFETY OF COVID-19 RELEASE Despite Adverse Reactions
NEW YORK WEIGHS OR CARRY OUT THE LINE FOR COVID-19 VACCINE
FIRST FDA HEAD THINKS HIGHLY RESPONSIBLE NEW MUTATION OF COVID-19 IS ‘ALREADY IN THE US’
Johnson & Johnson claims that only one shot of Ad26.COV2.S elicits strong neutralizing antibodies in more than 90 percent of its volunteers in clinical trials.
These neutralizing antibodies work to prevent virus proteins from binding to human cells. A two-dose regimen was less reactogenic, but caused the antibodies.
Upcoming Phase 3 clinical trials, the final phase of vaccination trials, will confirm whether a second dose will provide additional benefits for efficacy or endurance, especially in the elderly.
‘Although all ongoing phase 3 studies of other Covid-19 vaccines have evaluated two-dose schedules, a single dose of Ad26.COV2.S elicited a strong humoral response from the majority of vaccine recipients, with the presence of S-binding and neutralizing antibodies in more than 90% of the participants, regardless of age group or vaccine dose, ”reads the published report.
Five serious adverse side effects were reported, including one participant temporarily admitted with fever. Other common adverse effects were migraine, myalgia, fatigue and pain at the injection site.
As the U.S. government struggles to allocate available vaccine doses to the initial population, a single-dose vaccine effective against COVID-19 exposure has “logical advantages over a two-dose vaccine, especially during a pandemic,” according to the authors of the study.
This may be due to the way the vaccine is made. CNN notes rather than using mRNA to communicate with human cells and arm them against COVID-19 pathogens, the Johnson & Johnson candidate contains an attenuated version of colds, called adenovirus 26, to elicit an immune response to kill the body to recognize and fight COVID-19 particles. .
Johnson & Johnson in particular acknowledged that a lack of minority groups characterized the representation of study participants.
Despite promising results in early trials, The New York Times write that the company is behind the production, and the federal government is waiting for more than 60 million doses. It is understood that the company will catch up by March.
STUDY FROM CHINA’S CDC PROPOSALS WUHAN MAY 10 TIMES COVID-19 FALSE AS REPORT
A NEW VARIANT OF THE CORONAVIRUS IN THE UK: WHAT YOU NEED TO KNOW
FROM THE LABOR BANK TO THE UPPER ARM: HOW COVID-19 BELKSTONE BECOMES
5,000 BODY CASES AND 60 MORGU Trucks Shipped to Divided California